InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,418.86
(
1.39%
)
US TECH 100
18,454.80
(
2.21%
)
Dow Jones
39,683.78
(
0.83%
)
Brent Oil
80.34
(
-1.55%
)
Bitcoin
60,903.46
(
2.60%
)
Post# of 252869
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120263
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Katsche post# 171263

Friday, 12/13/2013 4:45:06 AM

Friday, December 13, 2013 4:45:06 AM

Post# of 252869

ABBV/ENTA—Therefore, the SVR12 for GT1b naive for Pearl III (450+267+333) must be between 95-98%. The figures for GT1b [treatment-experienced] (Pearl II) must be between 90% and 97%.

Are you referring to the ribavirin arms or the non-ribavirin arms of PEARL-2 and PEARL-3? The purpose of these two trials is to find out if ribavirin is needed in TE GT1b and TN GT1b, respectively (#msg-94927196).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up